Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Neuropharmacology. 2010 Dec 23;60(4):561–571. doi: 10.1016/j.neuropharm.2010.12.022

Fig. 9.

Fig. 9

Effect of restraint stress and selective CRF2 receptor blockade on baseline startle amplitude. Values shown are mean ± SEMs and were calculated from the startle stimulus alone trials that were used to calculate percent PPI. X-axis shows Pretreatment (ICV infusion)/Treatment (absence or presence of restraint). Startle amplitude was assessed 30 minutes after restraint termination on days 1, 3, and 5. Restraint decreased startle amplitude (*p < 0.01 vs. No Restraint, main effect). ASV-30 pretreatment did not alter the restraint-induced decrease in startle amplitude.